Anti-Parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 6, 2012, Pages 768-773

  Zhang, Zhen ^a,b   Li, Xuping ^b   Xie, Wen jie ^c   Tuo, Houzhen ^b   Hintermann, Samuel ^d   Jankovic, Joseph ^b   Le, Weidong ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Diana Helis Henry Medical Research Foundation   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Inflammation; Lactacystin; Neuroprotection; Nurr1 gene activator; Parkinson's disease; Ubiquitin proteasome system

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; LACTACYSTIN; NUCLEAR RECEPTOR RELATED FACTOR 1; SEROTONIN; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MEDIAL FOREBRAIN BUNDLE; MICROGLIA; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROTAROD TEST; SUBSTANTIA NIGRA;

ACETYLCYSTEINE; ANIMALS; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; MICE; MICE, INBRED C57BL; MICROGLIA; MOTOR ACTIVITY; NEOSTRIATUM; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; PARKINSONIAN DISORDERS; PROTEASOME ENDOPEPTIDASE COMPLEX; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBSTANTIA NIGRA; TRANSCRIPTIONAL ACTIVATION; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84867742272     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712803581155     Document Type: Article

References (40)

1. Jankovic, J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry, 2008, 79(4), 368-376.
2. Hornykiewicz, O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv. Neurol., 1993, 60, 140-147.
3. Youdim, M.B.; Riederer, P. Understanding Parkinson's disease. Sci. Am., 1997, 276(1), 52-59.
4. Siderowf, A.; Stern, M. Update on Parkinson disease. Ann. Intern. Med., 2003, 138(8), 651-658.
5. Saucedo-Cardenas, O.; Quintana-Hau, J.D.; Le, W.D.; Smidt, M.P.; Cox, J.J.; De Mayo, F.; Burbach, J.P.; Conneely, O.M. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. USA, 1998, 95(7), 4013-4018.
6. Zetterstrom, R.H.; Solomin, L.; Jansson, L.; Hoffer, B.J.; Olson, L.; Perlmann, T. Dopamine neuron agenesis in Nurr1-deficient mice. Science, 1997, 276(5310), 248-250.
7. Castillo, S.O.; Baffi, J.S.; Palkovits, M.; Goldstein, D.S.; Kopin, I.J.; Witta, J.; Magnuson, M.A.; Nikodem, V.M. Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol. Cell. Neurosci., 1998, 11(1-2), 36-46.
8. Jankovic, J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord., 2005, 20(Suppl 11), S11-S16.
9. Iwawaki, T.; Kohno, K.; Kobayashi, K. Identification of a potential nurr1 response element that activates the tyrosine hydroxylase gene promoter in cultured cells. Biochem. Biophys. Res. Commun., 2000, 274(3), 590-595.
10. Sacchetti, P.; Mitchell, T.R.; Granneman, J.G.; Bannon, M.J. Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J. Neurochem., 2001, 76(5), 1565-1572.
11. Hermanson, E.; Joseph, B.; Castro, D.; Lindqvist, E.; Aarnisalo, P.; Wallen, A.; Benoit, G.; Hengerer, B.; Olson, L.; Perlmann, T. Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. Exp. Cell. Res., 2003, 288(2), 324-334.
12. Volakakis, N.; Kadkhodaei, B.; Joodmardi, E.; Wallis, K.; Panman, L.; Silvaggi, J.; Spiegelman, B.M.; Perlmann, T. NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc. Natl. Acad. Sci. USA, 2010, 107(27), 12317-12322.
13. Jiang, C.; Wan, X.; He, Y.; Pan, T.; Jankovic, J.; Le, W. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp. Neurol., 2005, 191(1), 154-162.
14. Zhang, L.; Le, W.; Xie, W.; Dani, J.A. Age-related changes in dopamine signaling in Nurr1 deficient mice as a model of Parkinson's disease. Neurobiol. Aging, 2012, 33, 1001. e7-e16
15. Kadkhodaei, B.; Ito, T.; Joodmardi, E.; Mattsson, B.; Rouillard, C.; Carta, M.; Muramatsu, S.; Sumi-Ichinose, C.; Nomura, T.; Metzger, D.; Chambon, P.; Lindqvist, E.; Larsson, N.G.; Olson, L.; Bjorklund, A.; Ichinose, H.; Perlmann, T. Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci., 2009, 29(50), 15923-15932.
16. Saijo, K.; Winner, B.; Carson, C.T.; Collier, J.G.; Boyer, L.; Rosenfeld, M.G.; Gage, F.H.; Glass, C.K. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammationinduced death. Cell, 2009, 137(1), 47-59.
17. Hintermann, S.; Chiesi, M.; von Krosigk, U.; Mathe, D.; Felber, R.; Hengerer, B. Identification of a series of highly potent activators of the Nurr1 signaling pathway. Bioorg. Med. Chem. Lett., 2007, 17(1), 193-196.
18. Snyder, H.; Wolozin, B. Pathological proteins in Parkinson's disease: focus on the proteasome. J. Mol. Neurosci., 2004, 24(3), 425-442.
19. Moore, D.J.; West, A.B.; Dawson, V.L.; Dawson, T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci., 2005, 28, 57-87.
20. Le W.; Shen, C.; Jankovic, J. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist, 2009, 15(1), 28-35.
21. McGeer, P.L.; Yasojima, K.; McGeer, E.G. Inflammation in Parkinson's disease. Adv. Neurol., 2001, 86, 83-89.
22. Vernon, A.C.; Crum, W.R.; Johansson, S.M.; Modo, M. Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease. PLoS One, 2011, 6(2), e17269.
23. Li, X.P.; Xie, W.J.; Zhang, Z.; Kansara, S.; Jankovic, J.; Le, W.D. A Mechanistic Study of Proteasome Inhibition-Induced Iron Misregulation in Dopamine Neuron Degeneration. Neurosignals, 2012, Epub ahead of print.
24. Zhu, W.; Xie, W.; Pan, T.; Xu, P.; Fridkin, M.; Zheng, H.; Jankovic, J.; Youdim, M.B.; Le, W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J., 2007, 21(14), 3835-3844.
25. Petrucelli, L.; Dawson, T.M. Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann. Med., 2004, 36(4), 315-320.
26. Zhang, X.; Xie, W.; Qu, S.; Pan, T.; Wang, X.; Le, W. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun., 2005, 333(2), 544-549.
27. Pan, T.; Zhu, W.; Zhao, H.; Deng, H.; Xie, W.; Jankovic, J.; Le, W. Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res., 2008, 1222, 222-229.
28. Li, C.; Biswas, S.; Li, X.; Dutta, A.K.; Le, W. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin. J. Neurosci. Res., 2010, 88(11), 2513-2523.
29. Li, C.; Guo, Y.; Xie, W.; Li, X.; Janokovic, J.; Le, W. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Neurochem. Res., 2010, 35(10), 1546-1556.
30. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods, 2001, 25(4), 402-408.
31. Youdim, M.B. M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models. Parkinsonism Relat. Disord., 2012, 18(Suppl 1), S151-S154.
32. Langston, J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann. Neurol., 2006, 59(4), 591-596.
33. Olanow, C.W. The pathogenesis of cell death in Parkinson's disease--2007. Mov. Disord., 2007, 22(Suppl 17), S335-S342.
34. Sun, F.; Kanthasamy, A.; Anantharam, V.; Kanthasamy, A.G. Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease. Pharmacol. Ther., 2007, 114(3), 327-344.
35. Cook, C.; Petrucelli, L. A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. Biochim. Biophys. Acta, 2009, 1792(7), 664-675.
36. Bennett, E.J.; Bence, N.F.; Jayakumar, R.; Kopito, R.R. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell., 2005, 17(3), 351-365.
37. Bedford, L.; Hay, D.; Devoy, A.; Paine, S.; Powe, D.G.; Seth, R.; Gray, T.; Topham, I.; Fone, K.; Rezvani, N.; Mee, M.; Soane, T.; Layfield, R.; Sheppard, P.W.; Ebendal, T.; Usoskin, D.; Lowe, J.; Mayer, R.J. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci., 2008, 28(33), 8189-8198.
38. Xie, W.; Li, X.; Li, C.; Zhu, W.; Jankovic, J.; Le, W. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J. Neurochem., 2010, 115(1), 188-199.
39. Pan, T.; Kondo, S.; Zhu, W.; Xie, W.; Jankovic, J.; Le, W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol. Dis., 2008, 32(1), 16-25.
40. Smits, S.M.; Ponnio, T.; Conneely, O.M.; Burbach, J.P.; Smidt, M.P. Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. Eur. J. Neurosci., 2003, 18(7), 1731-1738.